ABSTRACT The purpose of the study was to examine whether the prolonged administration of the 3,-adrenoceptor partial agonist xamoterol could improve left ventricular diastolic function and affect the global remodeling process of the left ventricle after anterior myocardial infarction. In 22 patients with anterior myocardial infarction and single-vessel disease, left ventricular angiography (+ Millar) was performed under basal conditions 1 to 2 months after the acute myocardial infarction. Eight patients were then treated for 3 months with placebo and 14 were treated with xamoterol (200 mg bid) and a second left ventricular angiographic study was performed. Angiograms were digitized frame by frame to derive the diastolic pressure-volume relationship and to compute wall stress. An index of elastic myocardial stiffness was computed at a constant stress of 30 kdynes/cm2 before and after treatment. To evaluate changes in left ventricular shape, segmental areas in anterior and inferior segments were computed and compared at end-diastole and end-systole. After xamoterol, left ventricular end-diastolic pressure and mean diastolic wall stress decreased (from 24 5 to 15 + 5 mm Hg and from 57 + 32 to 38 + 22 kdynes/cm2, respectively; both p < .01 vs baseline and vs placebo). These changes were accompanied by a downward shift in the diastolic pressure-volume relationship and by a decrease in the index ofmyocardial stiffness from 526 + 270 to 371 + 194 kdynes/cm2 (p < .02). Left ventricular shape was not significantly altered by xamoterol but a significant remodeling of the left ventricular silhouette was evident at end-systole, as indicated by an improvement in the ratio (anterior segmental area/inferior segmental area) from 1.14 to 1.02 (median values; p < .025 vs baseline and vs placebo). It is concluded that impaired diastolic function after myocardial infarction is not entirely caused by fibrotic scar tissue but also by some active alterations in the function of viable myocardial areas that can be improved by therapy with xamoterol. Further studies are needed to determine whether the improvement in diastolic function and the systolic left ventricular remodeling are directly related. Circulation 77, No. 5, 1081-1089, 1988 RECENT cated that these beneficial effects on diastolic function were maintained during prolonged therapy.1T he purpose of this study was to examine whether the prolonged administration of xamoterol to patients with a previous myocardial infarction could significantly improve left ventricular diastolic function and affect the global remodeling process of the ventricle. Since other factors could influence the time course of change in left ventricular function in these patients, for example, infarct location, mitral regurgitation, and the presence of multiple-vessel disease, only patients with a recent transmural anterior myocardial infarction and single-vessel disease were enrolled in the study.
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Patients and methods
In a double-blind study of xamoterol vs placebo, 36 patients with ischemic heart disease were recruited. Of those, 22 (20 men, two women) had a first transmural anterior myocardial infarction (confirmed by typical history and electrocardiographic and enzymatic changes) in the territory perfused by the left anterior descending coronary artery. In 20 patients, the circumflex coronary artery, its marginal branch, and the right coronary artery were normal. In the two remaining patients, minor lesions were found on other branches (30% stenosis on the circumflex and right coronary arteries in one patient of the placebo group and 40% stenosis on the right coronary artery in one patient of the xamoterol group). Five of eight patients in the placebo group and six of 14 in the xamoterol group had poor to fair collateral development, while no collateral circulation was observed in the remaining patients. It is also noteworthy that in two patients (one in each group), no significant coronary lesion was found at the baseline study, suggesting that the myocardial infarction had been caused by a thrombus with secondary spontaneous thrombolysis.
The patients complained mainly of fatigue and dyspnea on exertion and were considered to be in functional class II of the New York Heart Association. All patients were in sinus rhythm and gave their informed consent for the study, which had been approved by the Ethical Committee of our institution. No complications or side effects of xamoterol were observed and the frequency of ventricular or supraventricular arrhythmias was unchanged.
Study protocol Baseline study. In all patients, cardioactive drugs were stopped for at least 3 days before the control study, which was performed between 4 and 8 weeks after the acute myocardial infarction. Catheterization of the left side of the heart was performed by the femoral approach with the patient in the fasting state and without premedication. Aortic Second study (3 months later). After the baseline study, patients were randomly assigned to placebo or xamoterol (onethird in the placebo group and two-thirds in treatment group). Tablets of xamoterol (200 mg) or matching placebo tablets were administered twice daily. Antiplatelet drugs (aspirin, dipyridamole) were allowed in all patients, but none received cardiac glycosides, diuretics, or vasodilators during the study period. The patients were seen at the outpatient clinic and compliance was checked by analysis of plasma for xamoterol. After 3 months of therapy, a second left heart catheterization and a metabolic study were performed with the same methods as in the baseline study. Average plasma level at the outpatient clinic 6 weeks after the start of the study was 74 + 31 ng/ml and at the time of second catheterization, it ranged from 75 to 353 ng/ml (mean 170 ± 74 ng/ml). Since the effective plasma concentrations to obtain 50%, 75%, and 95% of the maximal response to xamoterol range from 8 to 16, 24 to 50, and 150 to 314 ng/ml, respectively, all patients had effective plasma concentrations of the drug throughout the study.
Data analysis. All data were analyzed in a blinded fashion. Analog hemodynamic data filtered at 100 Hz were digitized every 2 msec and processed off-line by means of a HewlettPackard A900 computer as described previously.13 For the analysis of the angiographic data, both premature and postpremature beats were excluded. Ventricular silhouettes were outlined frame by frame with a light pen on a video screen. The digitized contours were preprocessed by a computer system (LVV Philips 100) that derived the correction factor for radiographic magnification and calculated volumes applying Simpson's rule. Using the long axis of the left ventricular silhouette as the reference system,"4 the left ventricle was divided into eight segments, four anterior and four inferior, and the areas of all segments were determined. The preprocessed data were then directed to an HP 21 MX computer for smoothing by a cubic spline method15 and for the computation of the various indexes of left ventricular function.
Midwall was determined at end-diastole in the anterobasal area and computed for other diastolic frames assuming a constant left ventricular mass. The mean diastolic wall stress was determined by averaging the data from the start of the ventricular filling to the peak of the R wave. An index of the left ventricular elastic properties, the elastic myocardial stiffness (E) was computed according to Kurnik et al. '7 This method assumed the model of a thick-walled prolate sphere and an exponential stress-strain relationship: stress = Cl + C4bc , where Cl, C4, C3 = constants calculated by a nonlinear best-fit method. These data were fitted from the minimum left ventricular pressure to the end of diastasis and E was then calculated at a constant physiologic level of stress (30 kdynes/cm2) from the equation E = C3 stress -Cl C3.
Regional systolic function was considered normal when the end-systolic area of a given segment fell within the range of values observed in normal ventricles'5 and abnormal when the end-systolic area was greater than the higher normal value for that segment. By this approach, three classes of segments were defined (normal segments, abnormal anterior segments, abnormal inferior segments) and the effects of therapy on each class was examined. Moreover, to evaluate the left ventricular shape change in the anterior and inferior segments, the areas of the four anterior and four inferior segments were summed at end-diastole (taken at the peak of the R wave) and at end-systole (taken at the maximum left ventricular pressure-volume ratio).
Blood oxygen content was determined with a Lex-02-CON Analyzer and lactate plasma concentrations were determined by an enzymatic method.'8 Angiographic cardiac output was calculated as the product of the stroke volume in the 30 degree right anterior oblique projection multiplied by the heart rate during angiography; these values were corrected by use of the regression equation obtained in our laboratory using phantoms. Systemic vascular resistance was calculated as: (mean aortic pressure/ cardiac output) x 80 (dynes-sec-cm-5).
Statistical analysis. All normally distributed data are presented as mean + SD and were compared with use of a paired t test. For the ratio (total anterior area/total inferior area), both the absolute values at end-systole and the changes observed during follow-up were skewed. Accordingly, the median values and the range are presented for this variable and the statistical comparisons before and after treatment were made by a rank test (Mann-Whitney U test). ' 
Results
Comparison of the placebo group and xamoterol group at baseline. At baseline, the two groups were comparable in terms of age, sex, coronary lesions, and degree of collateral development. The baseline ejection fraction (table 1), the diastolic left ventricular pressure-volume relationships ( figure 1, top) , and the index of myocardial elastic stiffness (580 + 297 and 526 + 260 in placebo and xamoterol groups, respectively; NS) were also well matched. while it tended to rise with xamoterol (1560 + 408 to 1880 + 680 dynes-sec-cm -5; p < .1 vs baseline), the differences between placebo and xamoterol being significant (-10% vs + 20%; p < .05). Several other significant differences were also observed between placebo and xamoterol groups.
An important difference concerned the changes in left ventricular end-diastolic pressure and in mean diastolic wall stress. Both variables were higher than normal in both groups at baseline and remained unchanged In the placebo group, the diastolic size of the normal segments was unchanged, but their end-systolic area decreased significantly. Since peak systolic and endsystolic pressures were unchanged, it is likely that the improved systolic function in the normal areas was related to a change in myocardial function, most likely hypertrophic changes rather than to a reduction in afterload. In contrast, in the xamoterol group, the use of the Starling mechanism was reduced in all classes of segments and systolic shortening improved in the anterior abnormal region but not in normal regions (table 2) . This relatively selective improvement in the anterior segments partially corrected the distortion of the ventricle at end-systole. The mechanisms for this relatively selective improvement in abnormal anterior segments after xamoteroi therapy are unclear. A similar finding was made after the short-term intravenous administration of xamoterol to patients with a previous myocardial infarction.9 A denervation supersensitivity to 3-stimulation was recently reported in noninfarcted areas apical to transmural infarction30 and could explain the greater response in the denervated area surrounding the scar tissue. An alternative hypothesis is that of a regional redistribution of blood flow related to the reduction in diastolic wall stress.
Thus, the difference in remodeling between groups mainly affected the normal segments and could not be explained by alterations in systolic or end-systolic pressure. Moreover, the shape of the end-systolic silhouette became more normal with xamoterol therapy but deteriorated slightly with placebo. This suggests that compensatory mechanisms, probably hypertrophy triggered by the elevated wall stress, were still active in normal zones with placebo but not with xamoterol. The difference in diastolic and systolic behavior in patients on xamoterol and placebo also resulted in different values of cardiac output. It appeared that some preload reserve was restored at the expense of resting cardiac output in patients on xamoterol while a "volume overload" type of increase in cardiac output, consistent with the model of McKay et al.,3 was taking place in patients on placebo.
Finally, one may speculate on whether real remodeling occurred during long-term xamoterol therapy or whether the changes observed simply reflect the shortterm action of the drug. Since the short-term effects of xamoterol were not measured in our patients, the shortand long-term responses cannot be compared. It is also difficult to compare the present data with those from other studies in which xamoterol was administered to patients with more severe left ventricular dysfunction and two-or three-vessel disease in whom sustained increases in cardiac output together with lower filling pressure were observed. 28 The changes in regional wall motion and diastolic function reported herewith are, however, comparable to those observed after intravenous xamoterol9 or during long-term treatment in patients with more severe coronary artery disease."1 The various differences observed in the placebo group nevertheless suggest that xamoterol is at least able to prevent some remodeling of the ventricle, if not to modify the remodeling process itself. The unfavorable changes in myocardial lactate extraction fraction seen in the placebo group, with lactate production in some patients, and the depression in an isovolumetric index of inotropic state relatively independent of preload and afterload20 in seven of these patients, further suggest that adaptative changes in left ventricular function and metabolism were less beneficial in the placebo group than in the xamoterol group.
Additional studies are needed to confirm these hypotheses. Precise measurements of anterior and inferior wall thickness are particularly important in this respect. Although it is evident that xamoterol improves diastolic function, it is also necessary to determine whether these elfects ofxamoterol on diastolic function are responsible for the improvements in exercise tolerance in patients with heart failure that have been reported in other studies. Furthermore, to understand the functional consequences of the balance between the agonist action of the drug in patients at rest and during moderate exercise and its antagonist action during maximal exercise,10 we need more detailed study that includes pressure-volume measurements in the leftventricle and right-sided pressure measurements not only at rest but also during exercise.
